Degradation of Androgen Receptor through Small Molecules for Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer is a prevalent malignancy in aging males, with castration-resistant prostate cancer (CRPC) posing a significant therapeutic challenge.
• Androgen receptor (AR) signaling is central to prostate cancer development and progression.
• Current AR antagonists like enzalutamide and ARN-509 are effective but face resistance due to AR mutations, such as F876L.

Purpose of the Study:

• To review novel therapeutic strategies for prostate cancer.
• To explore treatments targeting the androgen receptor degradation pathway.
• To address the unmet need for therapies effective against AR-mutant CRPC.

Main Methods:

• Literature review of recent studies on prostate cancer treatment resistance.
• Analysis of emerging therapeutic strategies targeting androgen receptor degradation.
• Discussion of novel agents and their mechanisms of action.

Main Results:

• Androgen receptor mutations, like F876L, can confer resistance to existing AR antagonists by converting them into agonists.
• Targeting the androgen receptor degradation pathway presents a promising strategy to overcome this resistance.
• Novel approaches focus on enhancing the breakdown of the androgen receptor protein.

Conclusions:

• Developing novel treatments that degrade the androgen receptor is crucial for overcoming resistance in advanced prostate cancer.
• Targeting AR degradation offers a new avenue for effective prostate cancer therapy, particularly in cases of AR antagonist resistance.
• Further research into AR-degrading agents is warranted for improved patient outcomes in prostate cancer.